Dozens of biotech companies are running low on cash and face an uphill struggle to raise fresh funds after “tourist” investors who snapped up their shares during the pandemic abandoned the sector.
數十家生物技術公司目前正陷入現金短缺，而且面臨著籌集新資金的艱難斗爭，原因是那些在大流行期間搶購其股票的“游客”投資者放棄了該行業。
您已閱讀2%（263字），剩余98%（10787字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。